Skip to main content
SpringerLink
Log in

Clinical and cognitive response to extended-release methylphenidate (Medikinet®) in attention deficit/hyperactivity disorder: Efficacy evaluation

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The objective of the study was to assess the efficacy of extended-release methylphenidate (Mph-ER) (Medikinet®; MEDICE Arzneimittel Pütter GmbH & Co KG, Iserlohn, Germany) in the pediatric population with attention deficit/hyperactivity disorder (ADHD); a parallel analysis of the validity of various tools for monitoring short-term clinical response to treatment was made.

Methods

This was a retrospective analysis of 94 children with ADHD who received treatment with Mph-ER. The ADHD Rating Scale-IV (ADHD-RS) was used to assess clinical efficacy. The following neuropsychological tests were used to assess cognitive-attentional efficacy: the faces test, the D2 test, the Magallanes visual attention scale (EMAV; Escalas Magallanes de Attencion Visual), and the Conners’ Continuous Performance Test II (CPT-II). The ADHD-RS scale was completed by the parents at the time of diagnosis and after 3 months of treatment. The tests were taken by patients both without treatment and under the effects of treatment. The results of these variables were transformed into Z values for subsequent analysis.

Results

In all, 84% of the patients lowered their ADHD-RS score with Mph-ER. Regarding the neuropsychological tests, a significant change was seen when the results of patients without treatment were compared with their later results with treatment. When the order of test conditions was reversed (with and then without treatment), the CPT-II was the only test for which there was still a significant difference.

Conclusion

Mph-ER improved attention and self-control from a clinical and cognitive point of view. Of those studied, the CPT-II was the most effective neuropsychological test for monitoring efficacy of Mph in the short-term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Connor DF. Stimulants. In: Barkley RA, ed. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York: Guilford Press; 2006:608–647.

    Google Scholar 

  2. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry. 1977;18:137–165.

    Article  PubMed  CAS  Google Scholar 

  3. Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs. 2004;18:1011–1030.

    Article  PubMed  CAS  Google Scholar 

  4. Spencer TJ, Biederman J, Wilens TE, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:409–432.

    Article  PubMed  CAS  Google Scholar 

  5. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9:573–603.

    Article  PubMed  CAS  Google Scholar 

  6. The MTA Cooperative Group. A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073–1086.

    Article  Google Scholar 

  7. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1088–1096.

    Article  Google Scholar 

  8. The MTA Cooperative Group. The NIMH MTA follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder (ADHD). Pediatrics. 2004;113:754–761.

    Article  Google Scholar 

  9. The MTA Cooperative Group. The NIMH MTA follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762–769.

    Article  Google Scholar 

  10. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46:989–1002.

    Article  PubMed  Google Scholar 

  11. Schachter HM, Pham B, King J, Langford S. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475.

    PubMed  PubMed Central  CAS  Google Scholar 

  12. Fischer R, Schütz H, Grossmann M, et al. Bioequivalence of a methylphenidate hydrochloride extended-release preparation: comparison of an intact capsule and an opened capsule sprinkled on applesauce. Int J Clin Pharmacol Ther. 2006;44:135–141.

    Article  PubMed  CAS  Google Scholar 

  13. Farré-Ribá A, Narbona J. Escalas Para la Evaluación del Déficit de Atención con Hiperactividad (EDAH). Madrid: TEA Ediciones; 1998.

    Google Scholar 

  14. Thurstone LL, Yela M. Caras, Test de Percepción de Diferencias. Adaptación Española. 9° Ed. Madrid: TEA Ediciones; 1991.

    Google Scholar 

  15. Brickenkamp R. D2, Test de Atención. Adaptación Española. Madrid: TEA Ediciones; 1997.

    Google Scholar 

  16. García M, Magaz A. EMAV, Escala Magallanes de Atención Visual. Bilbao: Editorial Grupo Albor Cohs; 2000.

    Google Scholar 

  17. Conners CK. Conners’ Continuous Performance Test (CPT II). New York: MHS; 2002.

    Google Scholar 

  18. Fernández-Jaén A, Martín Fernández-Mayoralas D, Calleja-Pérez B, et al. Efectos del metilfenidato en los procesos cognitivo-atencionales. Uso de los test de ejecución continuada. Rev Neurol. 2008;46(suppl. 1):S47–S49.

    PubMed  Google Scholar 

  19. Chacko A, Pelham WE, Gnagy EM, et al. Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:249–257.

    Article  PubMed  Google Scholar 

  20. Sinzig JK, Döpfner M, Plück J, et al. Does a morning dose of methylphenidate retard reduce hyperkinetic symptoms in the afternoon? [in German]. Z Kinder Jugendpsychiatr Psychother. 2004;32:225–233.

    Article  PubMed  Google Scholar 

  21. Döpfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of once-a-day extendedrelease methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004;13(suppl. 1):93–101.

    Google Scholar 

  22. Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28:1892–1908.

    Article  PubMed  CAS  Google Scholar 

  23. American Academy of Child and Adolescent Psychiatry. Summary of the practice parameters for the assessment and treatment of children, adolescents and adults with ADHD. J Am Acad Child Adolesc Psychiatry. 1997;36:1311–1317.

    Article  Google Scholar 

  24. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:1–15.

    Article  Google Scholar 

  25. Banaschewski T, Coghill D, Santosh P, et al. Longacting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476–495.

    Article  PubMed  Google Scholar 

  26. Newcorn JH, Halperin JM, Jensen PS, et al. Symptom profiles in children with ADHD: effects of comorbidity and gender. J Am Acad Child Adolesc Psychiatry. 2001;40:137–146.

    Article  PubMed  CAS  Google Scholar 

  27. Coghill DR, Rhodes SM, Matthews K. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;62:954–962.

    Article  PubMed  CAS  Google Scholar 

  28. Madaan V, Daughton J, Lubberstedt B, Mattai A, Vaughan BS, Kratovchvil CJ. Assessing the efficacy of treatments for ADHD: overview of methodological issues. CNS Drugs. 2008;22:275–290.

    Article  PubMed  CAS  Google Scholar 

  29. Wassenberg R, Hendriksen JG, Hurks PP, et al. Development of inattention, impulsivity, and processing speed as measured by the d2 test: results of a large cross-sectional study in children aged 7–13. Child Neuropsychol. 2008;14:195–210.

    Article  PubMed  Google Scholar 

  30. Rubio-Morell B, Martín-González R, Herreros-Rodríguez O, et al. Evaluación neuropsicológica de la eficacia del metilfenidato-OROS en el trastorno por déficit de atención/hiperactividad. Rev Neurol. 2008;46:602–608.

    PubMed  CAS  Google Scholar 

  31. Gordon M. The Gordon Diagnostic System. DeWitt, NY: Gordon Systems; 1983.

    Google Scholar 

  32. Gordon M, Barkley RA, Lovett BJ. Tests and Observational Measures. In: Barkley RA (ed). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York: Guilford Press; 2006:369–388.

    Google Scholar 

  33. Inoue Y, Inagaki M, Gunji A, et al. Response switching process in children with attentiondeficit-hyperactivity disorder on the novel continuous performance test. Dev Med Child Neurol. 2008;50:462–466.

    Article  PubMed  Google Scholar 

  34. Losier BJ, McGrath PJ, Klein RM. Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: a meta-analytic review. J Child Psychol Psychiatry. 1996;37:971–987.

    Article  PubMed  CAS  Google Scholar 

  35. Coons HW, Klorman R, Borgstedt AD. Effects of methylphenidate on adolescents with a childhood history of ADD: II. Information processing. J Am Acad Child Adolesc Psychiatry. 1987;26:368–374.

    Article  PubMed  CAS  Google Scholar 

  36. Fischer M, Newby RF, Gordon M. Who are the false negatives on continuous performance tests? J Clin Child Psychol. 1995;24:427–433.

    Article  Google Scholar 

  37. Garfinkel BD, Brown WA, Klee SH, et al. Neuroendocrine and cognitive responses to amphetamine in adolescents with a history of attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1986;25:503–508.

    Article  CAS  Google Scholar 

  38. Aman MG. Drugs, learning, and the psychotherapies. In: Werry JS (ed). Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York: Brunner/Mazel; 1978:79–108.

    Google Scholar 

  39. Riccio CA, Waldrop JJ, Reynolds CR, Lowe P. Effects of stimulants on the Continuous Performance Test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin Neurosci. 2001;13:326–335.

    Article  PubMed  CAS  Google Scholar 

  40. Musten LM, Firestone P, Pisterman S, Bennett S, Mercer J. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioural functions. J Am Acad Child Adolesc Psychiatry. 1997;36:1407–1415.

    Article  PubMed  CAS  Google Scholar 

  41. Byrne JM, Bawden HN, DeWolfe NA, Beattie TL. Clinical assessment of psychopharmacological treatment of preschoolers with ADHD. J Clin Exp Neuropsychol. 1998;20:613–627.

    Article  PubMed  CAS  Google Scholar 

  42. Pearson DA, Santos CW, Roache JD, et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:209–216.

    Article  PubMed  Google Scholar 

  43. Martin CA, Guenthner G, Bingcang C, et al. Measurement of subjective effects of methylphenidate in 11- to 15-year old children with attentiondeficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17:63–73.

    Article  PubMed  Google Scholar 

  44. Teicher MH, Lowen SB, Polcari A, et al. Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD. J Child Adolesc Psychopharmacol. 2004;14:219–32.

    Article  PubMed  Google Scholar 

  45. O’Toole K, Abramowitz A, Morris R, Dulcan M. Effects of methylphenidate on attention and nonverbal learning in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36:531–538.

    Article  PubMed  Google Scholar 

  46. Kupietz SS, Balka EB. Alterations in vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy. Psychopharmacology. 1976;50:29–33.

    Article  PubMed  CAS  Google Scholar 

  47. Weis R, Totten SJ. Ecological validity of the Conners’ Continuous Performance Test II in a schoolbased sample. J Psychoeduc Assess. 2004;22:47–61.

    Article  Google Scholar 

  48. Sadeh A, Gruber R, Raviv A. The effects of sleep restriction and extension on school-age children: what a difference an hour makes. Child Dev. 2003;74:444–455.

    Article  PubMed  Google Scholar 

  49. Trommer BL, Hoeppner JB, Lorber R, Armstrong K. Pitfalls in the use of a continuous performance test as a diagnostic tool in attention deficit disorder. J Dev Behav Pediatr. 1988;9:339–345.

    Article  PubMed  CAS  Google Scholar 

  50. Sostek AJ, Buchsbaum MS, Rapoport JL. Effects of amphetamine on vigilance performance in normal and hyperactive children. J Abnorm Child Psychol. 1980;8:491–500.

    Article  PubMed  CAS  Google Scholar 

  51. Riccio CA, Reynolds CR, Lowe PA. Monitoring medication effects with continuous performance tests. In: Riccio CA (ed). Clinical Applications of Continuous Performance Tests. Somerset, NJ: John Wiley & Sons, Inc; 2001:258–290.

    Google Scholar 

  52. Bannert M, Arbinger RS. Gender-related differences in exposure to and use of computers: results of a survey of secondary school students. Eur J Psychol Educ. 1996;11:269–282.

    Article  Google Scholar 

  53. Concannon PE, Tang YP. Management of attention deficit hyperactivity disorder: a parental perspective. J Paediatr Child Health. 2005;41:625–630.

    Article  PubMed  CAS  Google Scholar 

  54. Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. Child Care Health Dev. 2008;34:104–110.

    Article  PubMed  CAS  Google Scholar 

  55. Keulers EH, Hendriksen JG, Feron FJ, et al. Methylphenidate improves reading performance in children with attention deficit hyperactivity disorder and comorbid dyslexia: an unblinded clinical trial. Eur J Paediatr Neurol. 2007;11:21–28.

    Article  PubMed  Google Scholar 

  56. Kobel M, Bechtel N, Weber P, et al. Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. Eur J Paediatr Neurol. 2008;13:516–523.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropediatrics at “Quiron” Universitary Hospital, C/Diego de Veláquez, 1, 28223, Pozuelo de Alarcón, Madrid, Spain

    Alberto Fernández-Jaén & Daniel Martín Fernández-Mayoralas

  2. Centro CADE, Madrid, Spain

    Alexandra Pardos

  3. “Cirajas” Healthcare Center, Primary Care, Madrid, Spain

    Beatriz Calleja-Pérez

  4. Department of Neuropediatrics at the Hospital Infanta Leonor, Madrid, Spain

    Nuria Muñoz Jareño

Authors
  1. Alberto Fernández-Jaén
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Martín Fernández-Mayoralas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexandra Pardos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Beatriz Calleja-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nuria Muñoz Jareño
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Fernández-Jaén.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fernández-Jaén, A., Fernández-Mayoralas, D., Pardos, A. et al. Clinical and cognitive response to extended-release methylphenidate (Medikinet®) in attention deficit/hyperactivity disorder: Efficacy evaluation. Adv Therapy 26, 1097–1110 (2009). https://doi.org/10.1007/s12325-009-0083-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0083-9

Keywords

Search

Navigation